Skip to content

Medifast MED EBITDA margin

EBITDA margin at other companies

Eli Lilly logo
Eli LillyLLY
45.9%+14.4pp
WW International, Inc. logo
WW International, Inc.WW
11.1%+6.5pp
Herbalife logo
HerbalifeHLF
12%+0.7pp
Omada Health, Inc. Common Stock logo
Omada Health, Inc. Common StockOMDA
-7.3%
Lifevantage Corporation logo
Lifevantage CorporationLFVN
4.8%-2.5pp
The Beachbody Company logo
The Beachbody CompanyBODI
8.7%+5.9pp

Other financials

Income statement

See full
Revenue$76.0M-34.3%
Gross profit$51.8M-38.6%
Operating income-$3.3M-161%
Net income-$2.1M-175%
EPS (diluted)-$0.19-171%

Balance sheet

See full
Cash & equivalents$71.5M-22.0%
Total debt$16.1M+10.2%
Total equity$197.7M-6.3%
Total assets$252.0M-10.0%

Cash flow

See full
Operating cash flow$260.0K-92.4%
CapEx$1.1M-28.0%
Free cash flow-$836.0K-144%

Valuation

See full
Market cap$121.87M-17.4%
Enterprise value$66.44M+12.8%
P/S0.4×0.0×

Profitability

See full
Gross margin70.1%-3.8pp
Operating margin-4.7%-7.0pp
Net margin-5.8%-8.1pp
FCF margin5%-9.3pp

Returns & leverage

See full
Return on equity-9.8%-20.1pp
Debt / equity0.1×0.0×
Current ratio4.8×+1.3×

Where this comes from

Calculated from Medifast’s reported figures.

Based on trailing twelve months.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medifast's EBITDA margin?
Medifast (MED) reported EBITDA margin of -0.5% in Q1 2026.
How has Medifast's EBITDA margin changed year-over-year?
Medifast's EBITDA margin decreased by 144.1% year-over-year, from 1.2% to -0.5%.
What is the long-term trend for Medifast's EBITDA margin?
Over 4 years (2021 to 2025), Medifast's EBITDA margin has grown at a -84.8% compound annual growth rate (CAGR), from 14.6% to 0%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.